Compare Hims and Hers Health Inc (HIMS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Tango Therapeutics Inc. — how do they compare? Hims and Hers Health Inc trades at $27.6 (market cap $6.93B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Hims and Hers Health Inc is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Tango Therapeutics Inc. for 0 Days on average.
| HIMS | TNGX | |
|---|---|---|
Market Cap | $6.93B | $3.75B |
Volume | 9,771,956 | 9,619,106 |
Sector | Health | Health |
52-Week High | $62.76 | $32.90 |
52-Week Low | $14.52 | $7.50 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $7.64B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS trades at $29.71, down 3.04% today, amid ongoing securities class action lawsuits. The stock shows bullish technical signals with strong moving average support and key resistance at $32. Fundamentally, while revenue grew to $2.35B in 2025, the company posted a net loss of -$142M in 2026 with negative profit margins, though it maintains a solid gross margin of 68.4%.
The investment outlook is mixed: technical indicators suggest near-term upside potential toward the $32.17 consensus target, but fundamental weakness and legal overhangs pose significant risks. Analyst sentiment leans cautious with 65% hold ratings, reflecting concerns about profitability and regulatory challenges despite growth prospects.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
